AC BioTech, through its sister company AC BioScience, has in-licensed all the rights from Lexicon Pharmaceuticals for use of its preclinical and Phase 1 safety data for LX3305/LX2931 in oncology applications. All pre-clinical and regulatory studies were completed for this molecule in accordance with U.S. regulatory guidelines, and Phase 1 clinical studies were conducted under an Investigational New Drug application (IND). The molecule has an excellent safety profile in Phase 1 studies.
Following outstanding experimental efficacy results in pancreatic cancer applications, a favourable Scientific Advice received from the European Medicines Agency (EMA) now clears the way for a CTA to the regulatory authority in France to commence with an exploratory clinical trial Phase 2 in early 2024. Clinical trials will be carried out at the Salpétrière Hospital in Paris.
